ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program (Q44462012)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

expanded access

1 reference

based on heuristic

inferred from title

author name string

A G Pallis

1

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

D Mavroudis

2

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

N Androulakis

3

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

J Souglakos

4

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

C Kouroussis

5

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

V Bozionelou

6

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

I G Vlachonikolis

7

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

V Georgoulias

8

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

publication date

1 June 2003

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

40

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

301-307

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Epidermal growth factor receptor family in lung cancer and premalignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900079-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Kinase inhibitors in cancer therapy: a look ahead

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900079-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900079-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900079-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of amphiregulin in breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900079-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900079-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900079-5

7 January 2021

based on heuristic

inferred from DOI database lookup

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900079-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900079-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900079-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900079-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of quality-of-life outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900079-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS).

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900079-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Normative data and trends in quality of life from the Lung Cancer Symptom Scale (LCSS).

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900079-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900079-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900079-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0169-5002(03)00079-5

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44462012&oldid=2024801775"